US Edition
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
Rezpegaldesleukin showed a 30% reduction in alopecia severity and consistent eczema improvement in 393 patients, with FDA Fast Track designations for both conditions.
- On Saturday, Nektar Therapeutics showcased Phase 2b data for Rezpegaldesleukin at the American Academy of Dermatology Annual Meeting in Denver, demonstrating efficacy in both atopic dermatitis and alopecia areata.
- Rezpegaldesleukin functions as a novel, first-in-class regulatory T-cell stimulator targeting the interleukin-2 receptor complex to address underlying immunological dysfunction in inflammatory diseases.
- In the REZOLVE-AD study of 393 patients with atopic dermatitis, Rezpegaldesleukin demonstrated consistent reduction in mean Eczema Area and Severity Index scores compared to placebo regardless of baseline disease severity.
- Dr. David Rosmarin, Chair of Dermatology at Indiana University School of Medicine, reported high-dose Rezpegaldesleukin achieved a 28.2% mean reduction in Severity of Alopecia Tool scores at 36 weeks versus 11.2% with placebo.
- Nektar plans to initiate the Phase 3 ZENITH-AD program in the second quarter of 2026 to further evaluate Rezpegaldesleukin in moderate-to-severe atopic dermatitis patients.
24 Articles
24 Articles
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting (2026-03-28)
Raj Chovatiya, Associate Professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research, in an oral poster session entitled " Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2 b Efficacy, Safety, and Baseline Severity–...
New data highlight benefits of rezpegaldesleukin for severe alopecia areata
DENVER — Rezpegaldesleukin improved the severity of hair loss among adults with severe and very severe alopecia areata, according to results from the phase 2b REZOLVE-AA study.“This is a proof-of-concept study demonstrating a targeted treatment that can help patients with severe alopecia areata,” David Rosmarin, MD, chair of the department of dermatology, associate professor of
Coverage Details
Bias Distribution
- 87% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
